Use of the disulfiram/copper complex for breast cancer chemoprevention in MMTV‑erbB2 transgenic mice

Yang,Yanhui; Deng,Qian; Feng,Xiaoshan; Sun,Junjun

doi:10.3892/mmr.2015.3426

Use of the disulfiram/copper complex for breast cancer chemoprevention in MMTV‑erbB2 transgenic mice

Authors:
- Yanhui Yang
- Qian Deng
- Xiaoshan Feng
- Junjun Sun
View Affiliations

Affiliations: Department of General Surgery, The First Affiliated Hospital of Henan University of Science and Technology, Luoyang, Henan 471003, P.R. China, Department of Pharmacy, The Central Hospital of Luoyang, Luoyang, Henan 471000, P.R. China, Department of Oncology, The First Affiliated Hospital of Henan University of Science and Technology, Luoyang, Henan 471003, P.R. China
Published online on: March 4, 2015 https://doi.org/10.3892/mmr.2015.3426
Pages: 746-752

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The disulfiram/copper complex (DS/Cu) has been demonstrated to exert potent anti-tumor effects in various types of cancer. At present, whether DS/Cu has chemopreventive effects on breast cancer development remains to be fully elucidated. In the present study, using MMTV‑erbB2 transgenic mice, it was identified for the first time that DS/Cu treatment was able to inhibit cell growth in breast cancer cells while sparing normal cells in vitro, in addition to delaying the development of mammary tumor development in MMTV‑erbB2 transgenic mice in vivo. Morphological examination demonstrated that DS/Cu treatment resulted in cell proliferation inhibition and apoptosis activation in vitro and in vivo. Furthermore, the present study observed that DS/Cu may inhibit proliferation via inhibition of AKT and cyclin D1 signaling and promote apoptosis via c‑Jun N‑terminal kinase activation and suppression of nuclear factor κB signaling. These results suggested that DS/Cu treatment may be a promising therapy for the prevention of erbB2‑positive breast cancer.

View Figures

View References

1	DeSantis C, Ma J, Bryan L and Jemal A: Breast cancer statistics, 2013. CA Cancer J Clin. 64:52–62. 2014. View Article : Google Scholar
2	Green VL: Breast cancer risk assessment, prevention and the future. Obstet Gynecol Clin North Am. 40:525–549. 2013. View Article : Google Scholar : PubMed/NCBI
3	Allen-Petersen BL, Carter CJ, Ohm AM and Reyland ME: Protein kinase Cdelta is required for ErbB2-driven mammary gland tumorigenesis and negatively correlates with prognosis in human breast cancer. Oncogene. 33:1306–1315. 2014. View Article : Google Scholar
4	Chlebowski RT, Col N, Winer EP, Collyar DE, Cummings SR, Vogel VG III, Burstein HJ, Eisen A, Lipkus I and Pfister DG: American Society of clinical oncology technology assessment of pharmacologic interventions for breast cancer risk reduction including tamoxifen, raloxifene and aromatase inhibition. J Clin Oncol. 20:3328–3343. 2002. View Article : Google Scholar : PubMed/NCBI
5	Visvanathan K, Hurley P and Bantug E: Use of pharmacologic interventions for breast cancer risk reduction: american society of clinical oncology clinical practice guideline. J Clin Oncol. 31:2942–2962. 2013. View Article : Google Scholar : PubMed/NCBI
6	Jordan VC: Tamoxifen as the first targeted long-term adjuvant therapy for breast cancer. Endocr Relat Cancer. 21:R235–R246. 2014. View Article : Google Scholar : PubMed/NCBI
7	Sukawa Y, Yamamoto H, Nosho K, et al: HER2 expression and PI3K-Akt pathway alterations in gastric cancer. Digestion. 89:12–17. 2014. View Article : Google Scholar : PubMed/NCBI
8	Chiang CT, Way TD, Tsai SJ and Lin JK: Diosgenin, a naturally occurring steroid, suppresses fatty acid synthase expression in HER2-overexpressing breast cancer cells through modulating Akt, mTOR and JNK phosphorylation. FEBS Lett. 581:5735–5742. 2007. View Article : Google Scholar : PubMed/NCBI
9	Zhang MH, Man HT, Zhao XD, Dong N and Ma SL: Estrogen receptor-positive breast cancer molecular signatures and therapeutic potentials (Review). Biomed Rep. 2:41–52. 2014.PubMed/NCBI
10	Daniel KG, Gupta P, Harbach RH, Guida WC and Dou QP: Organic copper complexes as a new class of proteasome inhibitors and apoptosis inducers in human cancer cells. Biochem Pharmacol. 67:1139–1151. 2004. View Article : Google Scholar : PubMed/NCBI
11	Cen D, Brayton D, Shahandeh B, Meyskens FL Jr and Farmer PJ: Disulfiram facilitates intracellular Cu uptake and induces apoptosis in human melanoma cells. J Med Chem. 47:6914–6920. 2004. View Article : Google Scholar : PubMed/NCBI
12	Rizk SL and Sky-Peck HH: Comparison between concentrations of trace elements in normal and neoplastic human breast tissue. Cancer Res. 44:5390–5394. 1984.PubMed/NCBI
13	Daniel KG, Harbach RH, Guida WC and Dou QP: Copper storage diseases: Menkes, Wilsons and cancer. Front Biosci. 9:2652–2662. 2004. View Article : Google Scholar : PubMed/NCBI
14	Huang YL, Sheu JY and Lin TH: Association between oxidative stress and changes of trace elements in patients with breast cancer. Clin Biochem. 32:131–136. 1999. View Article : Google Scholar : PubMed/NCBI
15	Zhang H, Chen D, Ringler J, Chen W, Cui QC, Ethier SP, Dou QP and Wu G: Disulfiram treatment facilitates phosphoinositide 3-kinase inhibition in human breast cancer cells in vitro and in vivo. Cancer Res. 70:3996–4004. 2010. View Article : Google Scholar : PubMed/NCBI
16	Jørgensen CH, Pedersen B and Tønnesen H: The efficacy of disulfiram for the treatment of alcohol use disorder. Alcohol Clin Exp Res. 35:1749–1758. 2011. View Article : Google Scholar : PubMed/NCBI
17	Wang W, McLeod HL and Cassidy J: Disulfiram-mediated inhibition of NF-kappaB activity enhances cytotoxicity of 5-fluorouracil in human colorectal cancer cell lines. Int J Cancer. 104:504–511. 2003. View Article : Google Scholar : PubMed/NCBI
18	Chen D, Cui QC, Yang H and Dou QP: Disulfiram, a clinically used anti-alcoholism drug and copper-binding agent, induces apoptotic cell death in breast cancer cultures and xenografts via inhibition of the proteasome activity. Cancer Res. 66:10425–10433. 2006. View Article : Google Scholar : PubMed/NCBI
19	Doyon G, Zerbato J, Mellors JW and Sluis-Cremer N: Disulfiram reactivates latent HIV-1 expression through depletion of the phosphatase and tensin homolog. AIDS. 27:F7–F11. 2013. View Article : Google Scholar
20	Conticello C, Martinetti D, Adamo L, et al: Disulfiram, an old drug with new potential therapeutic uses for human hematological malignancies. Int J Cancer. 131:2197–2203. 2012. View Article : Google Scholar : PubMed/NCBI
21	Ursini-Siegel J, Schade B, Cardiff RD and Muller WJ: Insights from transgenic mouse models of ERBB2-induced breast cancer. Nat Rev Cancer. 7:389–397. 2007. View Article : Google Scholar : PubMed/NCBI
22	Li Y, Zhang Y, Hill J, Shen Q, Kim HT, Xu X, Hilsenbeck SG, Bissonnette RP, Lamph WW and Brown PH: The Rexinoid LG100268 prevents the development of preinvasive and invasive estrogen receptor negative tumors in MMTV-erbB2 mice. Clin Cancer Res. 13:6224–6231. 2007. View Article : Google Scholar : PubMed/NCBI
23	Lee HJ, So JY, DeCastro A, Smolarek A, Paul S, Maehr H, Uskokovic M and Suh N: Gemini vitamin D analog suppresses ErbB2-positive mammary tumor growth via inhibition of ErbB2/AKT/ERK signaling. J Steroid Biochem Mol Biol. 121:408–412. 2010. View Article : Google Scholar : PubMed/NCBI
24	Zhang GP, Han D, Liu G, Gao SG, Cai XQ, Duan RH and Feng XS: Effects of soy isoflavone and endogenous oestrogen on breast cancer in MMTV-erbB2 transgenic mice. J Int Med Res. 40:2073–2082. 2012. View Article : Google Scholar
25	Wattenberg LW: Chemoprevention of cancer. Cancer Res. 45:1–8. 1985.PubMed/NCBI
26	Bertram JS, Kolonel LN and Meyskens FL Jr: Rationale and strategies for chemoprevention of cancer in humans. Cancer Res. 47:3012–3031. 1987.PubMed/NCBI
27	Santner SJ, Dawson PJ, Tait L, Soule HD, Eliason J, Mohamed AN, Wolman SR, Heppner GH and Miller FR: Malignant MCF10CA1 cell lines derived from premalignant human breast epithelial MCF10AT cells. Breast Cancer Res Treat. 65:101–110. 2001. View Article : Google Scholar : PubMed/NCBI
28	Zhu J, Xiong G, Trinkle C and Xu R: Integrated extracellular matrix signaling in mammary gland development and breast cancer progression. Histol Histopathol. 2014.
29	Lövborg H, Oberg F, Rickardson L, Gullbo J, Nygren P and Larsson R: Inhibition of proteasome activity, nuclear factor-KappaB translocation and cell survival by the antialcoholism drug disulfiram. Int J Cancer. 118:1577–1580. 2006. View Article : Google Scholar
30	Li L, Yang H, Chen D, Cui C and Dou QP: Disulfiram promotes the conversion of carcinogenic cadmium to a proteasome inhibitor with pro-apoptotic activity in human cancer cells. Toxicol Appl Pharmacol. 229:206–214. 2008. View Article : Google Scholar : PubMed/NCBI
31	Brar SS, Grigg C and Wilson KS: Disulfiram inhibits activating transcription factor/cyclic AMP-responsive element binding protein and human melanoma growth in a metal-dependent manner in vitro, in mice and in a patient with metastatic disease. Mol Cancer Ther. 3:1049–1060. 2004.PubMed/NCBI
32	den Hollander P, Savage MI and Brown PH: Targeted therapy for breast cancer prevention. Front Oncol. 3:2502013. View Article : Google Scholar : PubMed/NCBI
33	Brown P: Prevention: targeted therapy-anastrozole prevents breast cancer. Nat Rev Clin Oncol. 11:127–128. 2014. View Article : Google Scholar : PubMed/NCBI